NovalGen Appoints Dr Laurent Fischer as Chair of the BoardLONDON, May 18, 2026 (GLOBE NEWSWIRE) -- NovalGen today announced the appointment of Dr Laurent Fischer, a globally recognized biopharmaceutical executive, as Non-Executive Chair of the Board of Directors with immediate effect. Dr Fischer brings more than 25 years of CEO and board leadership across public and private biotechnology companies, with a distinguished track record of advancing innovative therapies from discovery through approval and commercialization. His appointment marks an important milestone as NovalGen advances its next-generation AutoRegulation immunotherapy platform and lead asset, NVG-222, into later-stage development.
NovalGen to Begin World’s First Clinical Trial for a Self-Regulating ImmunotherapyLONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The world’s first therapeutic drug to be equipped with NovalGen’s pioneering AutoRegulation (AR) technology has been approved for evaluation in the clinic by the UK’s Medicine and Healthcare Products Regulatory Agency (MHRA).
NovalGen announces one oral and one poster presentation at the 65th American Society of Hematology Annual Meeting- Updated clinical data for ROR1xCD3 targeting TCE NVG-111 in hematological malignancies focussed on relapsed / refractory CLL and MCL-
NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of DirectorsTwo highly experienced industry executives who bring a wealth of leadership and drug development experience
NovalGen announces one oral and two poster presentations at the American Society of Hematology Annual Meeting-Updated clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL -- Pre-clinical data for a first in class half-life extended T Cell engager targeting ROR-1-
